Loading
Instead of treating everyone after surgery, test blood every few months and treat only when tumour DNA reappears.
Instead of treating every early TNBC patient after surgery, this idea tests blood every few months and escalates only when tumour DNA reappears. MRD-positive patients would be randomised to immediate ADC plus immunotherapy versus surveillance, while MRD-negative patients could omit adjuvant pembrolizumab. IMvigor011 proved the concept in bladder cancer, TNBC relapses early and sheds ctDNA, and the ZEST trial failed on feasibility rather than concept. The test is a platform trial in post-KEYNOTE-522 patients with serial Signatera-type testing, arms of Dato-DXd, sacituzumab govitecan or sac-TMT and a DFS endpoint. At early-clinical maturity it addresses the bottleneck Dormant cells and minimal residual disease.
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Dormant cells and minimal residual disease.
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Dormant cells and minimal residual disease.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Antibody-drug conjugate (ADC).
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).
Shares Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
Shares Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.